GW Pharma: Profitable In 2009

Cannabis medicine specialist GW Pharma has announced full-year profit of US$2.5mn. This strengthened financial position (compared with the US$13.6mn loss the company recorded in 2008) comes as the result of numerous milestone payments and an increase in the sale of its leading drug Sativex (delta-9-tetrahydrocannabinol), as well as reduced cash burn due to a greater proportion of research spending being funded by licensing partners.

To read the full article, please choose one of the following options: